Revolution Medicines (NASDAQ:RVMD) Hits New 1-Year High – Should You Buy?

Revolution Medicines, Inc. (NASDAQ:RVMD)’s share price hit a new 52-week high during trading on Monday . The company traded as high as $135.81 and last traded at $130.2630, with a volume of 5585324 shares. The stock had previously closed at $96.43.

Trending Headlines about Revolution Medicines

Here are the key news stories impacting Revolution Medicines this week:

• Positive Sentiment: Positive Phase 3 pancreatic cancer data showing improved survival is driving the rally; this outcome supports regulatory filings and commercialization prospects. RVMD Stock Rallies 41% on Positive Phase III Pancreatic Cancer Data
• Positive Sentiment: Major media and industry outlets report the trial success and survival benefit, corroborating the clinical significance and increasing investor confidence. Revolution Medicines’ experimental cancer pill helps improve survival
• Positive Sentiment: Broad financial press coverage highlights the late-stage win and market reaction, which can attract additional investor attention and liquidity. Pancreatic cancer drug daraxonrasib succeeds in late-stage trial
• Neutral Sentiment: Unusually large call-option buying was observed, suggesting some investors are speculatively leveraging the news; this can magnify volatility but does not change fundamentals by itself.
• Neutral Sentiment: Wedbush reaffirmed an “outperform” rating, which supports the bullish narrative but is not a new upgrade. Benzinga report
• Neutral Sentiment: Analysts and commentators note the data “wows” Wall Street but caution that additional catalysts (regulatory timeline, commercialization plans) will determine sustained upside. PDAC Data Wows Wall Street – Jury’s Out On Further Upside
• Negative Sentiment: Revolution announced proposed public offerings of $750M of common stock and $250M of convertible senior notes (plus underwriter options), which could dilute existing shareholders and pressure the stock once executed. Proposed offerings of common stock and convertible senior notes

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on RVMD. Weiss Ratings restated a “sell (d-)” rating on shares of Revolution Medicines in a report on Thursday, January 22nd. Wedbush restated an “outperform” rating on shares of Revolution Medicines in a report on Tuesday. Evercore reiterated an “outperform” rating on shares of Revolution Medicines in a report on Tuesday. Truist Financial upgraded Revolution Medicines to a “strong-buy” rating in a report on Wednesday, March 25th. Finally, Benchmark reiterated an “overweight” rating on shares of Revolution Medicines in a report on Tuesday, February 17th. Four research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Revolution Medicines presently has an average rating of “Buy” and an average price target of $78.94.

Revolution Medicines Stock Up 7.9%

The company has a 50-day moving average of $99.92 and a 200-day moving average of $84.28. The company has a market capitalization of $29.13 billion, a price-to-earnings ratio of -24.87 and a beta of 1.01. The company has a current ratio of 7.14, a quick ratio of 7.14 and a debt-to-equity ratio of 0.16.

Revolution Medicines (NASDAQ:RVMD) last announced its earnings results on Wednesday, February 25th. The company reported ($1.86) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.56) by ($0.30). During the same quarter in the prior year, the business earned ($1.12) earnings per share. On average, equities analysts predict that Revolution Medicines, Inc. will post -3.49 earnings per share for the current fiscal year.

Insider Buying and Selling at Revolution Medicines

In other Revolution Medicines news, CFO Jack Anders sold 2,753 shares of the business’s stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $99.48, for a total transaction of $273,868.44. Following the sale, the chief financial officer owned 125,512 shares in the company, valued at approximately $12,485,933.76. The trade was a 2.15% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Margaret A. Horn sold 4,583 shares of the business’s stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $99.48, for a total value of $455,916.84. Following the sale, the chief operating officer owned 157,570 shares in the company, valued at approximately $15,675,063.60. The trade was a 2.83% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 64,592 shares of company stock worth $6,488,732. 8.20% of the stock is owned by corporate insiders.

Institutional Trading of Revolution Medicines

A number of hedge funds have recently modified their holdings of RVMD. Nextech Invest Ltd. boosted its stake in shares of Revolution Medicines by 20.7% in the fourth quarter. Nextech Invest Ltd. now owns 7,601,087 shares of the company’s stock worth $332,472,000 after buying an additional 1,304,347 shares during the last quarter. Millennium Management LLC boosted its stake in shares of Revolution Medicines by 681.8% in the first quarter. Millennium Management LLC now owns 156,353 shares of the company’s stock worth $5,529,000 after buying an additional 136,353 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in shares of Revolution Medicines by 14.2% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 300,196 shares of the company’s stock worth $10,615,000 after buying an additional 37,345 shares during the last quarter. Invesco Ltd. boosted its position in Revolution Medicines by 19.3% during the second quarter. Invesco Ltd. now owns 227,019 shares of the company’s stock worth $8,352,000 after purchasing an additional 36,760 shares in the last quarter. Finally, Jump Financial LLC boosted its position in Revolution Medicines by 87.9% during the second quarter. Jump Financial LLC now owns 15,258 shares of the company’s stock worth $561,000 after purchasing an additional 7,137 shares in the last quarter. Hedge funds and other institutional investors own 94.34% of the company’s stock.

Revolution Medicines Company Profile

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.